2024. Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s433. DOI:https://doi.org/10.25251/skin.8.supp.433.